Amonafide

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Amonafide
Amonafide.svg
Systematic (IUPAC) name
5-amino-2-[2-(dimethylamino)ethyl]-1H-benzo[de]isoquinoline-1,3(2H)-dione
Clinical data
Trade names Xanafide, Quinamed
Identifiers
CAS Number 69408-81-7
ATC code none
PubChem CID 50515
ChemSpider 45804 YesY
UNII 1Q8D39N37L YesY
KEGG D10090 YesY
ChEMBL CHEMBL428676 YesY
Chemical data
Formula C16H17N3O3
Molar mass 283.325 g/mol
  (verify)

Amonafide (originally AS1413) (INN, trade names Quinamed and Xanafide) is a drug that is being studied in the treatment of cancer. It belongs to a novel family of chemotherapeutic drugs called Naphthalimides and is a potential topoisomerase inhibitor and DNA intercalator.

It is being developed as an anti-cancer therapy by Antisoma.[1]

As of 2008, it is in Phase III clinical trials. e.g. In March 2010 it is Phase III trial against secondary acute myeloid leukaemia (AML).[2] In June 2010, it gained an FDA Fast Track Status for the treatment of Secondary Acute Myeloid Leukaemia.

See also[edit]

References[edit]

  1. ^ http://www.genengnews.com/news/bnitem.aspx?name=78979622
  2. ^ http://clinicaltrials.gov/ct2/show/NCT00715637 "Phase III Randomized Study of Amonafide (AS1413) and Cytarabine Versus Daunorubicin and Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- the ACCEDE Study"

External links[edit]

 This article incorporates public domain material from the U.S. National Cancer Institute document "Dictionary of Cancer Terms".